FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Nephrolithiasis

Therapeutic area intelligence for Nephrolithiasis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Icahn →

Recent signals(2)

ClinicalAugust 16, 2026

Trial Comparing Single-Tract vs Multi-Tract Nephrolithotomy for Complex Renal Stones

A randomized trial by Al-Azhar University is assessing the non-inferiority of single-tract nephrolithotomy versus multi-tract nephrolithotomy for complex renal stones, focusing on stone-free rates and various secondary outcomes.

ClinicalAugust 16, 2026

Icahn School of Medicine initiates trial for CaOx stone prevention strategies

The Icahn School of Medicine at Mount Sinai is conducting a randomized controlled trial to compare empiric therapy versus selective therapy for calcium oxalate stone prevention in 80 patients undergoing percutaneous nephrolithotomy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.